All Stories

Coherus to lose 30% of staff as part of Udenyca sale to Accord

Coherus BioSciences will see its workforce shrink once again as a result of the recent sale of its Neulasta biosimilar to Accord BioPharma.

Mar 11, 2025 - 12:31
 0
Coherus to lose 30% of staff as part of Udenyca sale to Accord
Coherus BioSciences will see its workforce shrink once again as a result of the recent sale of its Neulasta biosimilar to Accord BioPharma.
Read More

Tags:

Previous Article

Point S plans on being UK’s largest independent service network by 2035

Next Article

Moscow targeted by ‘massive’ Ukrainian drone attack

Related Posts

IQVIA launches digital tool for ordering lab tests and managing specimens

IQVIA launches digital tool for ordering lab tests and ...

Mar 4, 2025  0

FDA approves Medtronic’s adaptive deep-brain stimulator for Parkinson’s disease

FDA approves Medtronic’s adaptive deep-brain stimulator...

Feb 24, 2025  0

Roche to house its CVRM research work at Harvard's new research campus

Roche to house its CVRM research work at Harvard's new ...

Mar 7, 2025  0